Leading Spanish-based brain-computer interface (BCI) company INBRAIN Neuroelectronics has announced its new collaboration with Microsoft to explore artificial intelligence (AI) applications for real-time brain-computer interface therapeutics.
The strategic partnership will use Microsoft’s Azure AI infrastructure, including time-series large language models (LLMs) and advanced data analytics, to support and adapt INBRAIN’s neural platform and its individual patient signals.
The goal of these new neuro-tech collaborations is to redefine how neurological disorders are monitored and treated using real-time data and AI systems that operate autonomously.
“Our vision is to create the most intelligent, autonomous, and personalized interface between the nervous system and AI,” said Carolina Aguilar, CEO & Co-Founder of INBRAIN Neuroelectronics in a statement. “By collaborating with Microsoft, we are merging our precision graphene neural technology with one of the world’s most advanced AI ecosystems.”
“This partnership moves us closer to a future where brain-computer interfaces don’t just decode or modulate neural activity—they understand and respond to the nervous system in real time, making the nervous system the body’s operating system,” Aguilar said.
“This collaboration highlights the next frontier of AI,” said Clare Barclay, President of Enterprise and Industry, EMEA at Microsoft. “INBRAIN’s work sits at the intersection of neuroscience, bioelectronics, and AI, and we are proud to provide the computational infrastructure and data foundation that will accelerate their mission to improve neurological health worldwide.”
NBRAIN’s brain interface utilizes graphene, a thin and signal-friendly material composed of a single layer of carbon atoms, which can safely interface with the human brain. This allows the INBRAIN system to read and influence brain signals with incredible accuracy.
Combining this with smart AI that learns and adapts in real time, the platform can deliver personalized therapies automatically, creating a new type of AI-powered brain-computer interface that can adjust brain activity as needed and may one day even be used to target other organs in the body.
INBRAIN’s BCIs are aiming to deliver capabilities with benefits for those diagnosed with Parkinson’s disease and epilepsy, as well as future applications for psychiatric or memory disorders.
Consumer Brand BCI Integration. But what about privacy?
INBRAIN states that the company is committed to ensuring patient privacy and data security by implementing strict protocols and safeguards, particularly when collaborating with major technology partners such as Microsoft.
“Patient privacy and data security are central to our mission and are integrated into every layer of the INBRAIN platform,” Aguilar said in an email to The Debrief. “All patient data is encrypted end-to-end, de-identified for analysis, and protected through strict role-based access controls that limit visibility to authorized clinical and research staff.”
“Our partnership with Microsoft leverages Azure’s healthcare-compliant, regulated infrastructure—not consumer-facing systems—and includes explicit contractual safeguards preventing Microsoft from accessing or repurposing patient data,” she said.
“We operate under GDPR, HIPAA, and all relevant MDR/IVDR requirements, ensuring that patient information remains secure, confidential, and entirely under medical governance,” Aguilar added. “Across all partnerships and technologies, maintaining patient safety, privacy, and data integrity is our highest priority.”
However, with real-time neural data being collected, who ultimately owns or has access to this sensitive information—the patient, INBRAIN, or Microsoft?
Aguilar explains that “Neural data generated through an INBRAIN device belongs to the patient, and access is tightly regulated under clinical trial protocols, institutional review board oversight, and all applicable privacy laws. INBRAIN does not commercialize patient data, and Microsoft does not access, store, or own patient-identifiable neural information.
“When secure cloud infrastructure is used for analysis, it is deployed within a healthcare-compliant environment,” Aguilar said, “where only authorized clinical and research personnel can access de-identified data. Microsoft’s role is limited to providing infrastructure—it does not control or use the clinical data in any way.”
This is the second BCI collaboration to have recently occurred between a neurotech company and a consumer brand. Earlier this year, Synchron announced its partnership with Apple to develop technology that allows users to control their iPhones and other Apple devices using their minds.
“At Apple, accessibility is part of our DNA,” said Tim Cook, Apple’s CEO, in a statement in May. “Making technology for everyone is a priority for all of us, and we’re proud of the innovations we’re sharing this year.”
“That includes tools to help people access crucial information, explore the world around them, and do what they love,” Cook said.
Chrissy Newton is a PR professional and the founder of VOCAB Communications. She currently appears on The Discovery Channel and Max and hosts the Rebelliously Curious podcast, which can be found on YouTube and on all audio podcast streaming platforms. Follow her on X: @ChrissyNewton, Instagram: @BeingChrissyNewton, and chrissynewton.com.